Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lb-100. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP5C known ✓ | P53041 | 2/20 | 1.00 |
| ▸ | PPP2CA known ✓ | P67775 | 1/20 | 1.00 |
| ▸ | TFPI2 | P48307 | 9/20 | 1.00 |
| ▸ | NPY4R | P50391 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | PPM1B | O75688 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lb-100 SCHEMBL13311584 | 1.00 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| Lb-100 SCHEMBL12390164 | 1.00 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| Lb-100 SCHEMBL19512780 | 1.00 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| Lb-100 SCHEMBL26377801 | 1.00 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| Lb-100 SCHEMBL2832350 | 1.00 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| Lb-100 SCHEMBL19501013 | 1.00 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| SCHEMBL14135374 | 0.87 | TFPI2 (0.77) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| SCHEMBL2332631 | 0.86 | TFPI2 (0.77) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| SCHEMBL12390209 | 0.85 | TFPI2 (0.74) | TFPI2PPP5CPPP2CANPY4RKDM4E | |
| SCHEMBL1572846 | 0.85 | TFPI2 (0.74) | TFPI2PPP5CPPP2CANPY4RKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260096280-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-04-02 | — | — | US | claimed |
| US-20260068416-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | BEIJING SUMMER SPROUT TECH CO LTD (CN) | 2026-03-05 | — | — | US | claimed |
| US-20250380610-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2025-12-11 | — | — | US | claimed |
| US-12440479-B2 | Prevention or treatment of chronic organ injury | GEORG-AUGUST-UNIVERSITAET GOETTINGEN, STIFTUNG OEFFENTLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2025-10-14 | — | — | US | claimed |
| WO-2025199602-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MITOGENS AND STRESS CONTROL PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | INSTITUTO BUTANTAN (BR) | 2025-10-02 | — | — | WO | claimed |
| US-20250208149-A1 | WEE1 COMPOUND FOR TREATING UTERINE SEROUS CARCINOMA | RECURIUM IP HOLDINGS, LLC | 2025-06-26 | — | — | US | claimed |
| EP-4565238-A1 | WEE1 COMPOUND FOR TREATING UTERINE SEROUS CARCINOMA | Recurium IP Holdings, LLC (US) | 2025-06-11 | — | — | EP | claimed |
| CN-120037234-A | Application of LB-100 in preparing medicament for treating osteoarthritis | 南方医科大学深圳医院 | 2025-05-27 | — | — | CN | claimed |
| US-11711969-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-25 | — | — | US | claimed |
| WO-2023133371-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| US-20230006153-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-01-05 | — | — | US | claimed |
| CN-110237257-B | Application of Ube3a ubiquitinated PP2A activator PTPA in treatment of Angel syndrome and autism | 中国科学院脑科学与智能技术卓越创新中心 | 2023-01-03 | — | — | CN | claimed |
| US-20220372054-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-11-24 | — | — | US | claimed |
| US-11495756-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2022-11-08 | — | — | US | claimed |
| WO-2022232135-A1 | METHODS OF TREATING CANCER AND ISCHEMIA DISEASES BY INHIBITION AND INTERVENTION OF ATR PROLYL ISOMERIZATION | THE UNIVERSITY OF TOLEDO (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022159150-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SMALL CELL LUNG CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-11374181-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2022-06-28 | — | — | US | claimed |
| CN-113854280-B | Low-temperature preservation solution and preparation method and application thereof | 创芯国际生物科技(广州)有限公司 | 2022-05-31 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250380610-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | LEF1, L1CAM, EMC1 | PPP5C 4766/4885PPP2CA 4598/4885TFPI2 3243/4885 |
| US-11711969-B2 | Organic electroluminescent materials and devices | RPS4X, NCOA4, KCNN4 | PPP5C 4524/4885PPP2CA 3474/4885TFPI2 4783/4885 |
| US-20250208149-A1 | WEE1 COMPOUND FOR TREATING UTERINE SEROUS CARCINOMA | WEE1, WEE2, CSDE1 | PPP5C 1119/4885PPP2CA 1861/4885TFPI2 615/4885 |
| US-20220372054-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ACAT1, SORD, CRAT | PPP5C 4357/4885PPP2CA 2347/4885TFPI2 4344/4885 |
| US-11495756-B2 | Organic electroluminescent materials and devices | L1CAM, EPCAM, SOD1 | PPP5C 4795/4885PPP2CA 3515/4885TFPI2 4008/4885 |
| US-20230006153-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, OTC | PPP5C 4537/4885PPP2CA 3972/4885TFPI2 3951/4885 |
| US-12440479-B2 | Prevention or treatment of chronic organ injury | FKBP2, DUSP3, FKBP1A | PPP5C 56/4885PPP2CA 21/4885TFPI2 320/4885 |
| US-20260096280-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | GLRA1, GLRA3, MSR1 | PPP5C 4836/4885PPP2CA 4211/4885TFPI2 4805/4885 |
| US-20260068416-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | LEF1, MLX, L1CAM | PPP5C 4510/4885PPP2CA 2570/4885TFPI2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.